Innovent Biologics' Mazdutide Outperforms Semaglutide in HbA1c Reduction and Weight Loss in Phase 3 Study

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Oct 27 2025

0mins

Source: NASDAQ.COM

Positive Clinical Trial Results: Innovent Biologics announced successful results from its fourth Phase 3 trial, DREAMS-3, for mazdutide, a dual GLP-1 and glucagon receptor agonist, in Chinese patients with type 2 diabetes and obesity.
Efficacy Compared to Semaglutide: At week 32, 48.0% of mazdutide patients achieved significant glycemic control and weight loss, outperforming the 21.0% in the semaglutide group, with notable reductions in HbA1c and body weight.
Safety Profile: The safety of mazdutide was consistent with previous studies, with no new safety concerns identified, and the most common adverse events were mild to moderate gastrointestinal symptoms.
Therapeutic Potential: The findings highlight mazdutide's potential as a next-generation treatment for type 2 diabetes and obesity, demonstrating superior efficacy in glycemic control and weight management compared to existing therapies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.